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ABSTRACT 
Objective: To develop and validate stability indicating HPTLC method for determination of clevidipine butyrate in synthetic mixture. 
Methods: The present study deals with development and validation of stability indicating HPTLC method for estimation of clevidipine butryate. 
Chromatographic separation was performed on aluminum plate pre coated with Silica Gel 60 F254 using toluene: ethyl acetate (8:2) as mobile 
phase. TLC scanner was set at wavelength of 370 nm.  
Results: Retention factor Rf 
Conclusion: A new, Simple, Accurate, Precise, Sensitive and economic stability indicating HPTLC method has been developed and validated for the 
determination of clevidipine and can be employed for stability indicating analysis. 
of clevidipine was found to be 0.49. The method was validated as per ICH guidelines. Calibration curve was in the range 
of 1000-6000ng/band. The correlation coefficient was found to be 0.999. The precision expressed by RSD was less than 2%. The accuracy of method 
was confirmed by recovery studies using standard addition method and recovery was found to be 99.03-99.57%. The drug was subjected to ICH 
prescribed hydrolytic, oxidative, photolytic and thermal stress conditions. Clevidipine and its degradation products were well resolved under 
experimental conditions. The method was validated according to ICH guidelines. The drug showed significant degradation in alkaline and acidic 
condition and slight degradation in oxidative condition. The drug was stable in thermal condition. 
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Clevidipine butyrate (CLEVI) is dihydropyridine L-type calcium 
channel blocker that is selective for vascular smooth muscle [1]. It is 
indicated for reduction of blood pressure when oral therapy is not 
possible [2]. It is available as lipid emulsion for intravenous infusion 
and is approved in US. It is marketed as Cleviprex by The Medicines 
Company [3]. It is effective in the treatment of both preoperative 
and post operative hypertension in adult cardiac surgery patients 
with rapid onset and short duration of action. Chemical name of 
CLEVI is methyl 5-{[(butanoyloxy) methoxy] carbonyl}-4-(2,3-
dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate. 
Literature survey reveals determination of CLEVI and its metabolite 
by HPLC method [4]. LC-MS/MS methods are reported for 
determination of CLEVI [5-7]. Various methods are reported for 
determination of related substances of clevidipine butyrate by HPLC 
method [9-11].  
Force degradation studies have an important role in the 
development of pharmaceuticals. ICH guidelines requires that 
stability of samples should be analysed by stability indicating assay 
method which is to be developed by stress testing in conditions like 
hydrolytic, oxidative, thermal and photolytic and validated. To the 
best of our knowledge stability indicating method of clevidipine by 
HPTLC method has not been reported. HPTLC method has several 
advantages over HPLC methods. It is economic, samples can be 
analysed with shorter run time, low mobile phase consumption per 
sample. It facilitates automatic sample application and scanning to 
the plate, can handle large no. of samples at a time and is sensitive.  
The objective of the present study was to develop simple, 
economical, specific, precise, accurate and reproducible HPTLC 
method development for the determination of clevidipine butyrate 
in bulk and synthetic mixture. The developed analytical method was 
validated for linearity, accuracy, precision, sensitivity and 
robustness as per ICH guidelines. 
MATERIALS AND METHODS 
Chemicals and Reagents  
Clevidipine butyrate (CLEVI) was purchased from Angene Chemical 
Ltd, China. Toluene, methanol, ethyl acetate of HPLC grade was 
purchased from SD Fine Chemical Ltd., Mumbai Pvt. Ltd. 
Instrumentation and chromatographic conditions 
Linomat 5 sample applicator (Camag, Switzeland), twin trough 
chamber (20 X 10 cm; Camag, Switzerland), TLC scanner IV(Camag, 
Switzerland), winCATS version 1.4.6 software (Camag, Switzerland), 
Hamilton microlitre syringe (Linomat syringe 659.0014, Hamilton 
Bonaduz Schweiz, Camag, Switzerland), UV chamber (Camag, 
Switzerland), precoated silica gel 60F254 aluminium plates (20X 20 
cm,100 mm thickness; E. Merck, Darmstadt, Germany) were used in 
the study. 
Optimized chromatographic conditions 
Standard solutions and sample solutions were applied to the HPTLC 
plates from the bottom and 10 mm from the side edges in the form 
of bands with the band length of 6 mm on the pre-coated silica gel 
aluminium plate 60 F 254 (20x 20 cm), 100 µm thickness, using 
Camag Linomat V sample applicator. The mobile phase was toluene: 
ethyl acetate (8:2). Mobile phase components were mixed prior to 
use and the development chamber was left to saturate with mobile 
phase vapor for 20 min before each run. Ascending method 
development was carried out to a migration distance of 80 mm. TLC 
plates were dried in a current of air with air dryer. Scanning was 
performed at wavelength of 370 nm reflectance absorbance mode, 
slit dimension 6 X 0.3 mm, micro), scanning speed 20 mm/sec, data 
resolution 100 µm/step, optical filter second order, filter factor 
(Savitsky Golay 7). The source of radiation was deuterium lamp 
emitting a continuous UV spectrum of 200 to 400 nm. Data was 
integrated with WINCATS software. 
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Preparation of solutions 
Standard solutions  
Standard stock solutions were prepared by dissolving 10 mg of 
CLEVI in methanol in 10 ml of volumetric flask. Different volumes of 
stock solution (1,2,3,4,5 and 6 µl) solution were applied as band to 
the HPTLC plate to make concentration in the range of 1000-
6000ng/band. 
Sample solution assay 
CLEVI marketed formulation could not be imported and it was 
prepared as laboratory synthetic mixture as per the given formula 
[13] in table 1. 
Forced degradation study  
Stock solution of CLEVI was prepared by dissolving 250 mg of CLEVI 
in 25 ml of methanol. This stock was used for degradation studies. 
 
Table 1: Composition of CLEVI synthetic mixture 
Composition %w/v 
Clevidipine 0.05 
Soyabean oil 20 
Glycerin 2.25 
Disodium Edetate 0.005 
Sodium citrate 0.1 
Egg yolk phospholipid 1.2 
Water for injection  upto 100% 
 
Acid degradation 
2.5 ml of stock solution of CLEVI was taken in 25 ml of volumetric 
flask, 1 ml of 1 N HCl was added and solution was heated in a water 
bath at 60 °C for 1 hour. The solution was cooled and neutralized 
with 1 N NaOH. Volume was made upto 25 ml with methanol to 
make concentration of 1 mg/ml. The solution was filtered through 
0.45µ Nylon 6,6 membrane syringe filter. From this solution 5 µl 
(5000 ng/band) was applied to HPTLC plate and development was 
carried out under optimized chromatographic conditions. 
Base degradation 
2.5 ml of stock solution of CLEVI was taken in 25 ml of volumetric 
flask, 1 ml of 0.01 N NaOH was added and solution was heated in a 
water bath at 60 °C for 1 hour. The solution was cooled and 
neutralized with 0.01 N HCl. Volume was made upto 25 ml with 
methanol to make concentration of 1 mg/ml. The solution was 
filtered through 0.45µ Nylon 6,6 membrane syringe filter. From this 
solution 5 µl (5000 ng/band) was applied to HPTLC plate and 
development was carried out under optimized chromatographic 
conditions. 
Oxidative degradation 
2.5 ml of stock solution of CLEVI was taken in 25 ml of volumetric 
flask, 1 ml of 3 % hydroegen peroxide was added. The solution was 
kept at room temperature for 1 hr. The solution was made upto 
volume with methanol. The solution was filtered through 0.45 µ 
Nylon 6,6 membrane syringe filter. From this solution 5 µl (5000 
ng/band) was applied to HPTLC plate and development was carried 
out under optimized chromatographic conditions. 
Thermal conditions  
25 mg of CLEVI was placed in oven at 80˚C for 8 d under dry heat 
conditions in the dark and then cooled to room temperature. Volume 
was made with methanol to get the concentration of 1 mg/ml. From 
this solution 5 µl (5000 ng/band) was applied to HPTLC plate and 
development was carried out under optimized chromatographic 
conditions. 
Photolytic degradation 
For the photochemical study, CLEVI equivalent to 25 mg was spread 
in 1 mm thickness on a petridish and exposed to 5383 Lux and 144 
UV/cm2
Validation 
for 11 d and volume was made upto 25 ml with methanol to 
make concentration of 1 mg/ml. From this solution 5 µl (5000 
ng/band) was applied to HPTLC plate and development was carried 
out under optimized chromatographic conditions. 
The method was validated as per ICH guidelines. 
Linearity 
The appropriate volume of standard API was spotted on a TLC plate 
to cover the range of 1000-6000 ng/band. The standard calibration 
graph of peak area versus concentration was plotted. Linearity was 
repeated thrice. The linearity of method was evaluated by linear 
regression analysis using the least square method. The slope and 
intercept were calculated.  
Accuracy (Recovery Study) 
Recovery studies were performed by standard addition method 
where known amount of standard samples were spiked to analyzed 
dosage form in triplicate. The base level quantity of formulation 
containing CLEVI used for spiking was 2500 ng/band. The %RSD 
and mean recovery were calculated. 
Precision 
The precision of proposed analytical method was done by 
repeatability (intra-day) and intermediate (inter-day) precision 
studies. The samples were analyzed three times on the same day 
(intra-day) and on three different days (inter-day precision). The % 
RSD value was calculated to determine intra-day and inter-day 
precision. 
Method sensitivity (Limit of detection and limit of 
quantification) 
The LOD and LOQ of the method were developed using regression 
equation. A series of standard preparation containing 1000-6000 
ng/band were prepared over different levels. Calibration graphs 
were plotted for the obtained area under curve of each level against 
the concentration. The LOD and LOQ were calculated using 
equations LOD=3.3xσ/S, LOQ= 10xσ/S, where σ is the standard 
deviation of y-intercept and S is the slope of calibration curve. 
Specificity 
Specificity is the ability of method to measure analyte in presence of 
its degradation products. Analytes were subjected to various stress 
conditions namely hydrolytic, oxidative, thermal and photolytic. 
Degraded samples were applied to the TLC plates and developed as 
mentioned previously. Developed densitograms were observed for 
resolution of degraded products. 
Robustness  
Robustness of analytical method is its capacity to remain unaffected by 
small but deliberate variation in method parameters. The HPTLC 
method parameters like saturation time of mobile phase, composition 
of mobile phase, time from spotting to development (solvent front). 
One factor at a time was changed and effect of Rf and peak area of the 
drug (3000 ng/band) were studied. The %RSD was calculated. 
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Development and optimization 
For selection of appropriate mobile phase for the development of 
CLEVI, trials were made by using solvents of different polarity, at 
different concentration levels. Several different composition of 
mobile phase system like water: methanol, methanol: acetonitrile, 
toluene: ethyl acetate were tried. Out the these, mobile phase 
toluene: ethyl acetate in a ratio of 8:2 was found to give sharp well 
defined peak at Rf
 
 value of 0.49±0.0057 for CLEVI which is shown in 
fig. 2. Densitogram with sharp defined peaks was obtained without 
any interference from analytes or excipients. 
 
Fig. 1: UV spectra of CLEVI 
 
 
Fig. 2: Optimised densitogram of CLEVI 
 
 
Fig. 3: Representative 3 D densitogram of linearity band of CLEVI 
 
Force degradation studies  
The results of force degradation study are summarized in table 1. 
During stress degradation experiments it was observed that CLEVI 
was more susceptible to alkaline and acidic hydrolysis than 
oxidative, thermal and photolytic degradation. 
 
 
Fig. 4: Representative densitogram of CLEVI standard 
 
 
Fig. 5: Representative densitogram of CLEVI synthetic mixture 
 
 
Fig. 6: Representative densitogram of 1 N HCl at 60 ˚C for 1 h 
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Validation of developed stability indicating method  
The developed method was validated as per ICH guidelines for 
parameters like linearity, accuracy, specificity, sensitivity and 
robustness. The 3 D densitograms showed well resolved peaks. The 
linearity was evaluated by regression analysis. The linearity of 
densitograms is shown in Fig.3. The correlation coefficient was 
found to be greater than 0.999. The low values of LOD and LOQ 
indicate that developed method is sensitive to be used as stability 
indicating (table 2). Satisfactory % recovery studies and lower % 
RSD obtained in accuracy, precision, robustness (table 3, 4).  
Thus this indicated the proposed method is robust to minor changes 
in the experimental conditions in the experimental conditions and 
can give accurate and precise results without any interference from 
injectable emulsion for the analysis of drug in the formulation. 
 
Table 2: Forced degradation study of CLEVI 
 CLEVI (API) CLEVI (synthetic mixture) 
Stress condition Rf % Degradation   of degraded product Rf % Degradation  of degraded product 
1 N HCl 60 °C for 1 hr 0.01, 0.02 22.5% 0.01.,0.02 19.5% 
0.01 N NaOH 60 ° C for 1 h 0.27 45% 0.27 41% 
3% H2O2 0.27  RT for 1 hour 8.5% 0.27 6.3% 
Thermal 80 °C for 8 d -- No degradation ---- No degradation 
Photolytic  0.01 0.6% 0.01 0.4% 
 
 
Fig. 7: Representative densitogram of 0.01 N NaOH at 60 ˚C for 1 h 
 
 
Fig. 8: Representative densitogram of 3% H2O2 at RT for 1 h 
 
Fig. 9: Representative densitogram in Thermal at 80 °C for 8 d 
 
 
Fig. 10: Representative densitogram in Photolytic condition for 
11 d
 
Table 3: Result of linearity, range, precision, method sensitivity study 
Parameter CLEVI 
Concentration range (ng/band) 1000-6000 
Retention factor 0.493±0.005 
Regression equation Y=1.877x+2410 
Correlation coefficient (R2 0.999 ) 
Precision  
Inter-day (% RSD) 1.33 
Intra-day (%RSD) 1.16 
Method sensitivity  
LOD(ng/band) 403.22 
LOQ(ng/band) 1222.492 
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mean±SD % RSD % Recovery mean±SD % RSD 
2500 1250 1237.6 1237.8±1.71 0.142 99.02 99.03±0.14 0.14 
2500 2500 2488.2 2488.6±1.59 0.069 99.5 99.54±0.06 0.06 
2500 3750 3732.5 3733.96±1.55 0.041 99.57 99.57±0.04 0.04 
n = number of determinations, SD= Standard Deviation, %RSD =%Relative Standard Deviation 
 
Table 5: Robustness study for the developed method (n=3) 
Condition Parameter Rf % RSD (Mean)±SD  Area (mean±SD) %RSD 
Mobile phase composition 7.8:2.2 0.47±0.005 1.21 8085.6±111.18 1.37 
 8.2: 1.8 0.52±0.005 1.10 8023.26±75.9  0.94 
Saturation of mobile phase 17 min 0.48±0.005 1.19 8052.46±99.1 1.23 
 23 min 0.49±0.005 1.17 7911.83±65.74 0.82 
Solvent front 7.5 cm 0.46±0.005 1.23 8054.96±101.24 1.25 
 8.5 cm 0.52±0.005 1.10 7939.53±106.37 1.3 
Wavelength 368 0.48±0.005 1.19 8075.25±61.42 0.76 
 372 0.49±0.005 1.07 8022.33±62.98 0.78 
n = number of determinations, SD= Standard Deviation, %RSD =% Relative Standard Deviation  
 
DISCUSSION 
Force degradation studies play an important role in the development 
of pharmaceuticals. The results of degradation studies helps in 
development of stability indicating method. The ICH Q1A guideline 
states that the validated stability indicating test methods must be 
performed to monitor the shelf life of drug substance which are 
susceptible to change during storage and which are likely to affect the 
quality, safety, efficacy of formulation. HPTLC method has an 
advantage over HPLC methods in the form that the reported HPLC 
methods [9], method is developed by gradient method which is time-
consuming and method [10, 11] is isocratic with longer retention time 
while in hptlc method standard and sample can be analysed 
simultaneously on same TLC plate. Short equilibrium time, low solvent 
consumption, low volume of sample requirement, no preliminary 
treatment like filtration and degassing, more number of samples can 
be applied on TLC plate, shorter run time and less expensive are 
advantages of developed HPTLC method over reported HPLC method. 
From the development and validation studies it was found that the 
proposed method can resolve drug substances and degradation 
products in shorter time with optimum resolution.  
CONCLUSION 
The HPTLC method was developed on pre-coated silica gel using 
toluene: ethyl acetate (8:2) as mobile phase with densitometric 
detection at 370 nm. This study found that HPTLC method 
development for determination of CLEVI in synthetic mixture is 
accurate, precise, linear, highly sensitive, specific and robust. The 
developed method was found to be suitable for determination of 
CLEVI in bulk and synthetic mixture.  
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